Abstract
It is of interest to document the known data on CoVid-19 infection linked to type-2 diabetes. Hyperglycemia, inhibition of neutrophil chemotaxis, altered cytokine synthesis, phagocytic cell dysfunction, impaired T cell-mediated immune responses, and inadequate microbia were all seen in people with Diabetes. Individuals with diabetes have also been shown to elevate levels of the proinflammatory cytokine, especially IL-1, IL-6, and tumor necrosis factor-alpha (TNF-alpha), and different markers such as C reactive protein, D-dimer, and fibrinogen. This will prolong the cytokine storms and lead to severe illness in diabetic individuals with COVID-19 infection. The role of acute glycemic control after COVID- 19 manifestation on clinical outcomes has not been known in detail. Known data shows that hyperglycemia facilitates local viral replication in the lungs and impairs anti-viral immune response. Thus, acute glycemic management plays an important role in limiting viral replication and disease progression in patients with diabetes. The available evidence implicates diabetes as important risk factors impacting the clinical severity of SARS-CoV-2.